Serial neoGFAP outperforms total GFAP for monitoring and 6-month outcome discrimination after moderate to severe traumatic brain injury: an exploratory single-site cohort study

This resource from medRxiv (Neurology) ("Serial neoGFAP outperforms total GFAP for monitoring and 6-month outcome discrimination after moderate to severe traumatic brain injury: an exploratory single-site cohort study") addresses critical scientific questions within Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease. Research in this domain currently faces major translational bottlenecks, including rapid upper and lower motor neuron degeneration, TDP-43 proteinopathy mislocalization, and high clinical heterogeneity in survival trajectories. By focusing on key thematic elements (medRxiv Clinical, Clinical Neurology, intensive care and critical care medicine, ALS), this work contributes empirical evidence toward understanding how molecular, cellular, or systems-level alterations relate to core disease pathways such as plasma/CSF Neurofilament Light Chain (NfL), C9orf72/SOD1/FUS genetics, cryptic exon biomarkers, and ALSFRS-R slopes. Integrating these findings into the broader open science ecosystem helps reduce fragmentation across independent laboratories and accelerates hypothesis verification.

Methodologically, this preprint integrates Clinical Neurology, Preprint Article within a CNS Experimental / Clinical Model framework (cohort/experimental samples documented in source protocol). Curated via medRxiv (Neurology) (DOI: 10.64898/2026.09.01.26361862), the analytical approach provides structured insights into Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease pathophysiology. Evaluating the reported outcomes alongside Clinical Neurology, Preprint Article technical specifications allows researchers to benchmark effect sizes, assay sensitivity, and experimental reproducibility against established reference cohorts.

Researchers and computational neuroscientists can reuse this resource across multiple secondary workflows: (1) Cross-Cohort Harmonization & Meta-Analysis — combining these Clinical Neurology, Preprint Article records with complementary repositories (such as OpenNeuro, DANDI, Agora, or Europe PMC) to increase statistical power; (2) Computational Benchmarking & Machine Learning — utilizing the documented features (medRxiv Clinical, Clinical Neurology, intensive care and critical care medicine, ALS) as training, validation, or out-of-distribution test sets for predictive biomarker discovery in Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease; and (3) Experimental Protocol Alignment — referencing the study design (CNS Experimental / Clinical Model, cohort/experimental samples documented in source protocol) to calibrate sample size calculations (power analysis) and endpoint selection for upcoming preclinical or clinical studies.

Because this record is indexed as a preprint, its experimental conclusions have not yet completed formal journal peer review; downstream clinical or therapeutic decisions should await peer-reviewed validation. Specifically, when interpreting Clinical Neurology, Preprint Article results in Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease, researchers must control for confounding variables (such as age, sex, post-mortem interval, scanner/instrument drift, or medication state) and verify compliance with open-access attribution requirements (cc_by_nc_nd).